Hormone Level Assessment in Women Taking Tri-Cyclen Lo

Introduction to Hormone Suppression

Ovarian function cannot be reliably assessed during hormonal contraceptive use because the exogenous hormones fundamentally alter the hypothalamic-pituitary-gonadal (HPG) axis, as stated by the National Comprehensive Cancer Network 1, 2

Anti-Müllerian hormone (AMH) is not affected by exogenous estrogen or progesterone, making it the only useful marker of ovarian reserve in women on hormonal contraception, according to the Journal of Clinical Oncology 1, 3

The American College of Obstetricians and Gynecologists recommends that hormone testing, such as measuring FSH and estradiol, has value when assessing menopausal status after discontinuing oral contraceptives, as suggested by the National Comprehensive Cancer Network 2, 4
For women approaching menopause (age ≥40-60 years), the National Comprehensive Cancer Network recommends stopping the oral contraceptive completely and waiting at least 7-14 days before measuring hormones, as stated in the MMWR Recommendations and Reports 5
The National Comprehensive Cancer Network suggests that for women <60 years, amenorrhea for ≥12 months plus FSH and estradiol in postmenopausal range confirms menopause 2, 4

The Centers for Disease Control and Prevention advises against interpreting withdrawal bleeding as evidence of ovarian function, as this is pharmacologic withdrawal from exogenous hormones, not true menstruation, as stated in the MMWR Recommendations and Reports 5